• AbbVie is preparing to present new clinical data from its blood cancer portfolio at the European Hematology Association 2026 Congress.
• The company will share multiple oral and poster presentations on both investigational and approved therapies, including detailed subgroup analyses from pivotal trials.
• Updates will cover safety and efficacy data for medicines such as epcoritamab and VENCLEXTA, along with insights from large Phase 3 studies.

For investors tracking NYSE:ABBV, the focus on hematology comes as the stock trades at $224.95, with a return of 21.3% over the past year and 83.9% over three years. Over five years, the stock shows a 134.9% return, while performance year to date is down 1.9%. In the shorter term, the share price is up 3.6% over the past week and 10.9% over the past month.

This new blood cancer data may be relevant for how you think about AbbVie’s oncology footprint and the mix of its potential future revenue drivers. As conference results and clinician feedback emerge, attention is likely to center on how therapies such as epcoritamab and VENCLEXTA fit into evolving standards of care across different blood cancers.

Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$224.95, AbbVie trades about 11% below the US$253.55 analyst price target range midpoint.
• ✅ Simply Wall St Valuation: The stock is assessed as trading around 49% below an estimated fair value.
• ✅ Recent Momentum: The share price is up 10.9% over the past 30 days.

There's only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's company report for the latest analysis of AbbVie's Fair Value.

Key Considerations

• 📊 Fresh blood cancer data at EHA 2026 could influence views on AbbVie’s oncology pipeline and the durability of its revenue mix.
• 📊 Watch efficacy and safety readouts for epcoritamab and VENCLEXTA, plus any subgroup results that hint at broader or narrower use in clinical practice.
• ⚠️ AbbVie still has four flagged risks including high debt and dividends not fully covered by earnings, so balance pipeline excitement with balance sheet and payout coverage.

Dig Deeper

For the full picture including more risks and rewards, check out the complete AbbVie analysis. Alternatively, you can check out the community page for AbbVie to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.